Neurological Deterioration in Wilson's Disease-Types, Etiology, Course, and Management.


Journal

Discovery medicine
ISSN: 1944-7930
Titre abrégé: Discov Med
Pays: United States
ID NLM: 101250006

Informations de publication

Date de publication:
Apr 2024
Historique:
medline: 26 4 2024
pubmed: 26 4 2024
entrez: 26 4 2024
Statut: ppublish

Résumé

Wilson's disease (WD) is an inherited disorder of copper metabolism in which pathological copper accumulation, mainly in the liver and the brain, leads to hepatic and/or neuropsychiatric signs and symptoms. Chelators and zinc salts can successfully induce negative copper balance in many patients; however, neurological deterioration may still be observed. This phenomenon can be divided into: (1) early 'paradoxical' neurological deterioration, which usually develops in the first 6 months of anti-copper treatment and may be commonly related to drug type, or (2) late neurological deterioration, which mostly occurs after 6 months of treatment and is often related either to non-compliance with treatment, overtreatment resulting in copper deficiency, or adverse drug reactions. Another explanation, especially for early neurological deterioration, is natural WD progression, which can be difficult to differentiate from drug-related deterioration, but usually leads to a worse outcome. There is still no consensus on how to define neurological deterioration in WD using scales or biomarkers, how to distinguish it from the natural disease progression, its risk factors, and optimal management. This narrative review, based on the current literature, aims to provide definitions, prevalence, pathological mechanisms and factors related to neurological deterioration, and also proposes schemes for diagnosis and treatment.

Identifiants

pubmed: 38665014
pii: 1713496732058-883842582
doi: 10.24976/Discov.Med.202436183.61
doi:

Substances chimiques

Copper 789U1901C5
Chelating Agents 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

646-654

Auteurs

Tomasz Litwin (T)

Second Department of Neurology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.

Agnieszka Antos (A)

Second Department of Neurology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.

Jan Bembenek (J)

Department of Neurophysiology, Institute Psychiatry and Neurology, 02-957 Warsaw, Poland.

Anna Cz Onkowska (A)

Second Department of Neurology, Institute of Psychiatry and Neurology, 02-957 Warsaw, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH